Scholarlink

Background <p>Universal tumor testing is increasingly recommended for Lynch syndrome (LS). However, data involving younger Japanese patients are still limited. This study aimed to prospectively evaluate the prevalence and clinicopathologic profile of DNA mismatch repair (MMR)–deficient (dMMR) endometrial cancers (EC) in patients aged under 50&#xa0;years, and characterize immunohistochemical (IHC) loss patterns and genetic testing results.</p> Methods <p>Patients with EC aged under 50&#xa0;years who consented to study participation were prospectively enrolled at a single Japanese institution. Diagnostic specimens underwent MMR IHC (MLH1, MSH2, MSH6, and PMS2). Clinicopathologic variables were compared between proficient MMR (pMMR) and dMMR.</p> Results <p>Among 111 patients, 26 (23.4%) had dMMR. Grades differed when dichotomized as G1 versus G2–G3 (p &lt; 0.01). FIGO stage distribution also varied between groups (p = 0.035). Among dMMR tumors, IHC patterns were loss of MLH1/PMS2 (n = 12), loss of MSH2/MSH6 (n = 8), and isolated loss of MSH6 (n = 6). Of the 12 (46.2%) patients with dMMR who underwent germline testing, 9 had LS (MLH1/PMS2 loss: 3/5; MSH2/MSH6 loss: 4/4; MSH6 isolated loss: 2/3). The overall dMMR prevalence in this young cohort was comparable to that in all-age series from multiple regions. This represents a minimum prevalence of LS in the overall study cohort, as germline testing was performed only in a subset of patients with dMMR tumors.</p> Conclusions <p>In this prospective Japanese cohort, approximately one in four patients with EC had dMMR, with clinicopathologic features skewing toward a higher grade. Notably, many dMMR tumors were grade 2–3, suggesting that a substantial proportion of patients may fall outside the conventional criteria for fertility-sparing treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and clinicopathologic features of mismatch repair–deficient endometrial cancer in Japanese patients younger than 50 years: a single-center prospective observational study

  • 期刊论文

  • 发表日期：

    2026年4月9日

查看全文
  • Hidetaka Nomura,
  • Akiko Abe,
  • Atsushi Fusegi,
  • Shogo Yamaguchi,
  • Tsubasa Kon,
  • Eitaro Funada,
  • Yuri Kuratomi,
  • Toshiaki Watanabe,
  • Mayumi Kamata,
  • Risako Ozawa,
  • Shogo Nishino,
  • Motoko Kanno,
  • Sachiho Netsu,
  • Yoichi Aoki,
  • Makiko Omi,
  • Sanshiro Okamoto,
  • Mayu Yunokawa,
  • Arisa Ueki,
  • Akiko Tonooka,
  • Hiroyuki Kanao

摘要

Background

Universal tumor testing is increasingly recommended for Lynch syndrome (LS). However, data involving younger Japanese patients are still limited. This study aimed to prospectively evaluate the prevalence and clinicopathologic profile of DNA mismatch repair (MMR)–deficient (dMMR) endometrial cancers (EC) in patients aged under 50 years, and characterize immunohistochemical (IHC) loss patterns and genetic testing results.

Methods

Patients with EC aged under 50 years who consented to study participation were prospectively enrolled at a single Japanese institution. Diagnostic specimens underwent MMR IHC (MLH1, MSH2, MSH6, and PMS2). Clinicopathologic variables were compared between proficient MMR (pMMR) and dMMR.

Results

Among 111 patients, 26 (23.4%) had dMMR. Grades differed when dichotomized as G1 versus G2–G3 (p < 0.01). FIGO stage distribution also varied between groups (p = 0.035). Among dMMR tumors, IHC patterns were loss of MLH1/PMS2 (n = 12), loss of MSH2/MSH6 (n = 8), and isolated loss of MSH6 (n = 6). Of the 12 (46.2%) patients with dMMR who underwent germline testing, 9 had LS (MLH1/PMS2 loss: 3/5; MSH2/MSH6 loss: 4/4; MSH6 isolated loss: 2/3). The overall dMMR prevalence in this young cohort was comparable to that in all-age series from multiple regions. This represents a minimum prevalence of LS in the overall study cohort, as germline testing was performed only in a subset of patients with dMMR tumors.

Conclusions

In this prospective Japanese cohort, approximately one in four patients with EC had dMMR, with clinicopathologic features skewing toward a higher grade. Notably, many dMMR tumors were grade 2–3, suggesting that a substantial proportion of patients may fall outside the conventional criteria for fertility-sparing treatment.